Business
Results of AGM on June 16, 2025 – Update Statement
PureTech Health plc has provided an update following its June 16, 2025, Annual General Meeting, noting that while all resolutions passed, over 20% of votes opposed Resolutions 2 and 9, concerning the Directors' Remuneration Report and the re-election of Ms. Mazumdar-Shaw. The company engaged with shareholders representing nearly 50% of issued share capital, who advised focusing on UK remuneration principles despite US operational challenges. The Remuneration Committee has reviewed practices, including equity grants, with full details to be in the 2025 Annual Report. The Board believes Ms. Mazumdar-Shaw adds significant value and is addressing administrative scheduling conflicts impacting her Board meeting attendance. Disclaimer*
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n10 December 2025\nPureTech Health plc\n \nResults of Annual General Meeting on June 16, 2025 - Update Statement\n \nIn accordance with Provision 4 of the UK Corporate Governance Code, PureTech (\"PureTech\" or the \"Company\") today provides an update in respect of the results of its Annual General Meeting (AGM) held on June 16, 2025. While all resolutions were approved by shareholders, more than 20% of votes were cast against Resolutions 2 and 9, relating to the Directors' Remuneration Report and the re-election of Ms. Mazumdar-Shaw as a Director, respectively.\n \nBuilding on prior year practice, and consistent with the Company's commitment to maintaining constructive, transparent dialogue with its shareholders, the Company has continued to actively engage with shareholders throughout 2025. Since the 2025 AGM, the Board has taken further steps to understand the views of shareholders. Specifically, the Company wrote to shareholders representing approximately two-thirds of the Company's issued share capital[1] to offer engagement with the Chair of the Board. Following that initial outreach, meetings were held with shareholders representing nearly 50% of issued share capital1 during the month of July. While a range of topics was discussed, shareholders provided feedback encouraging the Company to focus on alignment with UK remuneration principles, while recognizing the challenges associated with operating as a US-based company. Following these engagements, the Remuneration Committee has reviewed the Company's remuneration practices, including the quantum of equity grants for management. Full details of the Remuneration Committee's decisions will be disclosed in the 2025 Annual Report and Accounts, to be published in 2026.\n \nWith respect to the re-election of Ms. Mazumdar-Shaw, the Board believes that she contributes significant value to the Company, while acknowledging the scheduling conflict that impacted her attendance at Board meetings in 2024. The Company notes that the scheduling conflict impacting attendance was administrative in nature and is committed to implementing appropriate measures to ensure optimal Director attendance at Board meetings going forward.\n \nThe Board would like to thank the shareholders who have engaged with the Company during this process. The Board will continue to eng...